Feasibility and effectiveness of unintended pregnancy prevention with low-dose mifepristone combined with misoprostol before expected menstruation
STUDY QUESTION What is the efficacy of maintaining or restoring non-pregnant status with low-dose mifepristone combined with misoprostol administered before expected menstruation? SUMMARY ANSWER Low-dose mifepristone and misoprostol administered at the time of expected menstruation was effective and...
Gespeichert in:
| Veröffentlicht in: | Human reproduction (Oxford) 2015-12, Vol.30 (12), p.2794-2801 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2801 |
|---|---|
| container_issue | 12 |
| container_start_page | 2794 |
| container_title | Human reproduction (Oxford) |
| container_volume | 30 |
| creator | Li, Cui-Lan Chen, Dun-Jin Deng, Yi-Fan Song, Li-Ping Mo, Xue-Tang Liu, Kai-Jie |
| description | STUDY QUESTION
What is the efficacy of maintaining or restoring non-pregnant status with low-dose mifepristone combined with misoprostol administered before expected menstruation?
SUMMARY ANSWER
Low-dose mifepristone and misoprostol administered at the time of expected menstruation was effective and safe in maintaining or restoring non-pregnant status, with no obvious menstrual disturbance.
WHAT IS KNOWN ALREADY
Menstrual regulation involves the medical or mechanical stimulation of uterine sloughing in women with up to 2–3 weeks of menstrual delay. Low-dose mifepristone plus misoprostol is efficacious for termination of ultra-early pregnancy (≤35 days of amenorrhoea) with no obvious menstrual disturbance.
STUDY DESIGN, SIZE, DURATION
A total of 678 women fulfilled all criteria and were recruited. Seventeen women dropped out after deciding to remain pregnant and 11 others were lost to follow-up. Thus, data from 650 women who completed the procedure were included in analyses. Participants were enrolled at any time during their menstrual cycle and administered medication 1 day before expected menstruation. The end of the study was defined on a per-patient basis as the date of completion of the post-treatment menstrual cycle. The primary outcome was the efficacy of abortion induction (for pregnant women) or menstrual regulation (for non-pregnant women).
PARTICIPANTS, SETTING, METHODS
Women with regular menstrual cycles (25–35 days) were voluntarily recruited for this study between February 2012 and December 2014. Serum β-hCG was measured before mifepristone intake. Mifepristone (50 mg) was administered orally 1 day before expected menstruation and 200 µg misoprostol was administered orally on the day of expected menstruation. Efficacy, disturbance in bleeding patterns in the treatment and post-treatment cycles, satisfaction with the treatment, and subsequent contraception preference were analysed.
MAIN RESULTS AND THE ROLE OF CHANCE
Retrospective analysis of serum β-hCG levels at admission indicated that 23.3% (158/678) of the women were pregnant. The success rate for pregnancy termination was 98.6% (136/138). Two women (1.5%, 2/138) had ongoing pregnancy that was subsequently terminated surgically. The overall bleeding induction rate within 7 days was 98.3% (639/650), with 100% (138/138) in pregnant participants and 97.9% (501/512) in non-pregnant participants. Most pregnant and non-pregnant participants experienced no significant menstrual disturbance during |
| doi_str_mv | 10.1093/humrep/dev239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1733192126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/humrep/dev239</oup_id><sourcerecordid>1733192126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-405572baf95cb4a3192aa38ea9f6bc0fc6e16e5f08161e9d18f76ff9647d3e823</originalsourceid><addsrcrecordid>eNqFkb1OwzAUhS0EoqUwsiKPLKH-SdxkRBUFpEosMEeOc02NEjvETktfgyfGpQVGJl_Jn889xwehS0puKCn4dDW0PXTTGtaMF0doTFNBEsYzcozGhIk8oVTQETrz_o2QOObiFI2YSEnGBBmjzwVIbyrTmLDF0tYYtAYVzBoseI-dxoM1NoCtocZdD69WWrXdTZEIxlm8MWGFG7dJaucBt0ZD1xsfnAWsXFsZGx9-M63xrutdvGpwBdr1gOGji8si0IL1oR_kTvEcnWjZeLg4nBP0srh7nj8ky6f7x_ntMlEpz0ISE2QzVkldZKpKJacFk5LnIAstKkW0EkAFZJrkMTUUNc31TGhdiHRWc8gZn6DrvW409T6AD2V0qKBppAU3-JLO-E6UMhHRZI-q6N_3oMuYsZX9tqSk3NVQ7mso9zVE_uogPVQt1L_0z7__7XZD94_WFx05mMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1733192126</pqid></control><display><type>article</type><title>Feasibility and effectiveness of unintended pregnancy prevention with low-dose mifepristone combined with misoprostol before expected menstruation</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Li, Cui-Lan ; Chen, Dun-Jin ; Deng, Yi-Fan ; Song, Li-Ping ; Mo, Xue-Tang ; Liu, Kai-Jie</creator><creatorcontrib>Li, Cui-Lan ; Chen, Dun-Jin ; Deng, Yi-Fan ; Song, Li-Ping ; Mo, Xue-Tang ; Liu, Kai-Jie</creatorcontrib><description>STUDY QUESTION
What is the efficacy of maintaining or restoring non-pregnant status with low-dose mifepristone combined with misoprostol administered before expected menstruation?
SUMMARY ANSWER
Low-dose mifepristone and misoprostol administered at the time of expected menstruation was effective and safe in maintaining or restoring non-pregnant status, with no obvious menstrual disturbance.
WHAT IS KNOWN ALREADY
Menstrual regulation involves the medical or mechanical stimulation of uterine sloughing in women with up to 2–3 weeks of menstrual delay. Low-dose mifepristone plus misoprostol is efficacious for termination of ultra-early pregnancy (≤35 days of amenorrhoea) with no obvious menstrual disturbance.
STUDY DESIGN, SIZE, DURATION
A total of 678 women fulfilled all criteria and were recruited. Seventeen women dropped out after deciding to remain pregnant and 11 others were lost to follow-up. Thus, data from 650 women who completed the procedure were included in analyses. Participants were enrolled at any time during their menstrual cycle and administered medication 1 day before expected menstruation. The end of the study was defined on a per-patient basis as the date of completion of the post-treatment menstrual cycle. The primary outcome was the efficacy of abortion induction (for pregnant women) or menstrual regulation (for non-pregnant women).
PARTICIPANTS, SETTING, METHODS
Women with regular menstrual cycles (25–35 days) were voluntarily recruited for this study between February 2012 and December 2014. Serum β-hCG was measured before mifepristone intake. Mifepristone (50 mg) was administered orally 1 day before expected menstruation and 200 µg misoprostol was administered orally on the day of expected menstruation. Efficacy, disturbance in bleeding patterns in the treatment and post-treatment cycles, satisfaction with the treatment, and subsequent contraception preference were analysed.
MAIN RESULTS AND THE ROLE OF CHANCE
Retrospective analysis of serum β-hCG levels at admission indicated that 23.3% (158/678) of the women were pregnant. The success rate for pregnancy termination was 98.6% (136/138). Two women (1.5%, 2/138) had ongoing pregnancy that was subsequently terminated surgically. The overall bleeding induction rate within 7 days was 98.3% (639/650), with 100% (138/138) in pregnant participants and 97.9% (501/512) in non-pregnant participants. Most pregnant and non-pregnant participants experienced no significant menstrual disturbance during the treatment [96.3% (131/136) versus 97.6% (489/501)] or post-treatment [97.8% (133/136) versus 98.4% (493/501)] menstrual cycle. The general rate of satisfaction with the treatment was 96.7% (618/639). Generally, 36.0% (230/639) of participants preferred to use the regimen as a routine contraception method versus the 64.0% (409/639) who preferred to use it as a remedy for pregnancy prevention after unprotected sex (P < 0.001).
LIMITATIONS, REASONS FOR CAUTION
Study participants were recruited from a single region; further studies should include participants from multiple centres in different cities and nations. Given the uncertain efficacy of regimen reuse, the assessment of efficacy was based solely on the first treatment administration. Studies with larger samples and long-term follow-up may provide more data on whether repeated use of this regimen hampers its efficacy.
WIDER IMPLICATIONS OF THE FINDINGS
Menstrual regulation with low-dose mifepristone and misoprostol at expected menstruation can be efficacious and highly acceptable to maintain or restore non-pregnant status, which may have potential for routine contraception.
STUDY FUNDING/COMPETING INTEREST(S)
Support for this research was provided by the Start-Up Fund for Talents of the Third Affiliated Hospital of Guangzhou Medical University (2012), the Prevention and Control of Major Obstetric Disease major collaborative innovation project of the Educational Bureau of Guangzhou City (medical and health grant no. 13xt04, 2013), and the Collaborative Innovation Centre for Prevention and Control of Major Obstetric Disease collaborative innovation platform of the educational and financial departments of Guangdong Province (regional development grant, 2014). The authors declare no potential conflict of interest with respect to the research, authorship, and/or publication of this article.</description><identifier>ISSN: 0268-1161</identifier><identifier>EISSN: 1460-2350</identifier><identifier>DOI: 10.1093/humrep/dev239</identifier><identifier>PMID: 26405260</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Abortifacient Agents - administration & dosage ; Abortifacient Agents - therapeutic use ; Adolescent ; Adult ; Chorionic Gonadotropin - blood ; Contraceptive Agents - administration & dosage ; Contraceptive Agents - therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Menstrual Cycle - drug effects ; Menstruation - drug effects ; Middle Aged ; Mifepristone - administration & dosage ; Mifepristone - therapeutic use ; Misoprostol - administration & dosage ; Misoprostol - therapeutic use ; Pregnancy ; Treatment Outcome ; Young Adult</subject><ispartof>Human reproduction (Oxford), 2015-12, Vol.30 (12), p.2794-2801</ispartof><rights>The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2015</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-405572baf95cb4a3192aa38ea9f6bc0fc6e16e5f08161e9d18f76ff9647d3e823</citedby><cites>FETCH-LOGICAL-c435t-405572baf95cb4a3192aa38ea9f6bc0fc6e16e5f08161e9d18f76ff9647d3e823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26405260$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Cui-Lan</creatorcontrib><creatorcontrib>Chen, Dun-Jin</creatorcontrib><creatorcontrib>Deng, Yi-Fan</creatorcontrib><creatorcontrib>Song, Li-Ping</creatorcontrib><creatorcontrib>Mo, Xue-Tang</creatorcontrib><creatorcontrib>Liu, Kai-Jie</creatorcontrib><title>Feasibility and effectiveness of unintended pregnancy prevention with low-dose mifepristone combined with misoprostol before expected menstruation</title><title>Human reproduction (Oxford)</title><addtitle>Hum Reprod</addtitle><description>STUDY QUESTION
What is the efficacy of maintaining or restoring non-pregnant status with low-dose mifepristone combined with misoprostol administered before expected menstruation?
SUMMARY ANSWER
Low-dose mifepristone and misoprostol administered at the time of expected menstruation was effective and safe in maintaining or restoring non-pregnant status, with no obvious menstrual disturbance.
WHAT IS KNOWN ALREADY
Menstrual regulation involves the medical or mechanical stimulation of uterine sloughing in women with up to 2–3 weeks of menstrual delay. Low-dose mifepristone plus misoprostol is efficacious for termination of ultra-early pregnancy (≤35 days of amenorrhoea) with no obvious menstrual disturbance.
STUDY DESIGN, SIZE, DURATION
A total of 678 women fulfilled all criteria and were recruited. Seventeen women dropped out after deciding to remain pregnant and 11 others were lost to follow-up. Thus, data from 650 women who completed the procedure were included in analyses. Participants were enrolled at any time during their menstrual cycle and administered medication 1 day before expected menstruation. The end of the study was defined on a per-patient basis as the date of completion of the post-treatment menstrual cycle. The primary outcome was the efficacy of abortion induction (for pregnant women) or menstrual regulation (for non-pregnant women).
PARTICIPANTS, SETTING, METHODS
Women with regular menstrual cycles (25–35 days) were voluntarily recruited for this study between February 2012 and December 2014. Serum β-hCG was measured before mifepristone intake. Mifepristone (50 mg) was administered orally 1 day before expected menstruation and 200 µg misoprostol was administered orally on the day of expected menstruation. Efficacy, disturbance in bleeding patterns in the treatment and post-treatment cycles, satisfaction with the treatment, and subsequent contraception preference were analysed.
MAIN RESULTS AND THE ROLE OF CHANCE
Retrospective analysis of serum β-hCG levels at admission indicated that 23.3% (158/678) of the women were pregnant. The success rate for pregnancy termination was 98.6% (136/138). Two women (1.5%, 2/138) had ongoing pregnancy that was subsequently terminated surgically. The overall bleeding induction rate within 7 days was 98.3% (639/650), with 100% (138/138) in pregnant participants and 97.9% (501/512) in non-pregnant participants. Most pregnant and non-pregnant participants experienced no significant menstrual disturbance during the treatment [96.3% (131/136) versus 97.6% (489/501)] or post-treatment [97.8% (133/136) versus 98.4% (493/501)] menstrual cycle. The general rate of satisfaction with the treatment was 96.7% (618/639). Generally, 36.0% (230/639) of participants preferred to use the regimen as a routine contraception method versus the 64.0% (409/639) who preferred to use it as a remedy for pregnancy prevention after unprotected sex (P < 0.001).
LIMITATIONS, REASONS FOR CAUTION
Study participants were recruited from a single region; further studies should include participants from multiple centres in different cities and nations. Given the uncertain efficacy of regimen reuse, the assessment of efficacy was based solely on the first treatment administration. Studies with larger samples and long-term follow-up may provide more data on whether repeated use of this regimen hampers its efficacy.
WIDER IMPLICATIONS OF THE FINDINGS
Menstrual regulation with low-dose mifepristone and misoprostol at expected menstruation can be efficacious and highly acceptable to maintain or restore non-pregnant status, which may have potential for routine contraception.
STUDY FUNDING/COMPETING INTEREST(S)
Support for this research was provided by the Start-Up Fund for Talents of the Third Affiliated Hospital of Guangzhou Medical University (2012), the Prevention and Control of Major Obstetric Disease major collaborative innovation project of the Educational Bureau of Guangzhou City (medical and health grant no. 13xt04, 2013), and the Collaborative Innovation Centre for Prevention and Control of Major Obstetric Disease collaborative innovation platform of the educational and financial departments of Guangdong Province (regional development grant, 2014). The authors declare no potential conflict of interest with respect to the research, authorship, and/or publication of this article.</description><subject>Abortifacient Agents - administration & dosage</subject><subject>Abortifacient Agents - therapeutic use</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Chorionic Gonadotropin - blood</subject><subject>Contraceptive Agents - administration & dosage</subject><subject>Contraceptive Agents - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Menstrual Cycle - drug effects</subject><subject>Menstruation - drug effects</subject><subject>Middle Aged</subject><subject>Mifepristone - administration & dosage</subject><subject>Mifepristone - therapeutic use</subject><subject>Misoprostol - administration & dosage</subject><subject>Misoprostol - therapeutic use</subject><subject>Pregnancy</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0268-1161</issn><issn>1460-2350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkb1OwzAUhS0EoqUwsiKPLKH-SdxkRBUFpEosMEeOc02NEjvETktfgyfGpQVGJl_Jn889xwehS0puKCn4dDW0PXTTGtaMF0doTFNBEsYzcozGhIk8oVTQETrz_o2QOObiFI2YSEnGBBmjzwVIbyrTmLDF0tYYtAYVzBoseI-dxoM1NoCtocZdD69WWrXdTZEIxlm8MWGFG7dJaucBt0ZD1xsfnAWsXFsZGx9-M63xrutdvGpwBdr1gOGji8si0IL1oR_kTvEcnWjZeLg4nBP0srh7nj8ky6f7x_ntMlEpz0ISE2QzVkldZKpKJacFk5LnIAstKkW0EkAFZJrkMTUUNc31TGhdiHRWc8gZn6DrvW409T6AD2V0qKBppAU3-JLO-E6UMhHRZI-q6N_3oMuYsZX9tqSk3NVQ7mso9zVE_uogPVQt1L_0z7__7XZD94_WFx05mMQ</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Li, Cui-Lan</creator><creator>Chen, Dun-Jin</creator><creator>Deng, Yi-Fan</creator><creator>Song, Li-Ping</creator><creator>Mo, Xue-Tang</creator><creator>Liu, Kai-Jie</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>Feasibility and effectiveness of unintended pregnancy prevention with low-dose mifepristone combined with misoprostol before expected menstruation</title><author>Li, Cui-Lan ; Chen, Dun-Jin ; Deng, Yi-Fan ; Song, Li-Ping ; Mo, Xue-Tang ; Liu, Kai-Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-405572baf95cb4a3192aa38ea9f6bc0fc6e16e5f08161e9d18f76ff9647d3e823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Abortifacient Agents - administration & dosage</topic><topic>Abortifacient Agents - therapeutic use</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Chorionic Gonadotropin - blood</topic><topic>Contraceptive Agents - administration & dosage</topic><topic>Contraceptive Agents - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Menstrual Cycle - drug effects</topic><topic>Menstruation - drug effects</topic><topic>Middle Aged</topic><topic>Mifepristone - administration & dosage</topic><topic>Mifepristone - therapeutic use</topic><topic>Misoprostol - administration & dosage</topic><topic>Misoprostol - therapeutic use</topic><topic>Pregnancy</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Cui-Lan</creatorcontrib><creatorcontrib>Chen, Dun-Jin</creatorcontrib><creatorcontrib>Deng, Yi-Fan</creatorcontrib><creatorcontrib>Song, Li-Ping</creatorcontrib><creatorcontrib>Mo, Xue-Tang</creatorcontrib><creatorcontrib>Liu, Kai-Jie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Cui-Lan</au><au>Chen, Dun-Jin</au><au>Deng, Yi-Fan</au><au>Song, Li-Ping</au><au>Mo, Xue-Tang</au><au>Liu, Kai-Jie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility and effectiveness of unintended pregnancy prevention with low-dose mifepristone combined with misoprostol before expected menstruation</atitle><jtitle>Human reproduction (Oxford)</jtitle><addtitle>Hum Reprod</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>30</volume><issue>12</issue><spage>2794</spage><epage>2801</epage><pages>2794-2801</pages><issn>0268-1161</issn><eissn>1460-2350</eissn><abstract>STUDY QUESTION
What is the efficacy of maintaining or restoring non-pregnant status with low-dose mifepristone combined with misoprostol administered before expected menstruation?
SUMMARY ANSWER
Low-dose mifepristone and misoprostol administered at the time of expected menstruation was effective and safe in maintaining or restoring non-pregnant status, with no obvious menstrual disturbance.
WHAT IS KNOWN ALREADY
Menstrual regulation involves the medical or mechanical stimulation of uterine sloughing in women with up to 2–3 weeks of menstrual delay. Low-dose mifepristone plus misoprostol is efficacious for termination of ultra-early pregnancy (≤35 days of amenorrhoea) with no obvious menstrual disturbance.
STUDY DESIGN, SIZE, DURATION
A total of 678 women fulfilled all criteria and were recruited. Seventeen women dropped out after deciding to remain pregnant and 11 others were lost to follow-up. Thus, data from 650 women who completed the procedure were included in analyses. Participants were enrolled at any time during their menstrual cycle and administered medication 1 day before expected menstruation. The end of the study was defined on a per-patient basis as the date of completion of the post-treatment menstrual cycle. The primary outcome was the efficacy of abortion induction (for pregnant women) or menstrual regulation (for non-pregnant women).
PARTICIPANTS, SETTING, METHODS
Women with regular menstrual cycles (25–35 days) were voluntarily recruited for this study between February 2012 and December 2014. Serum β-hCG was measured before mifepristone intake. Mifepristone (50 mg) was administered orally 1 day before expected menstruation and 200 µg misoprostol was administered orally on the day of expected menstruation. Efficacy, disturbance in bleeding patterns in the treatment and post-treatment cycles, satisfaction with the treatment, and subsequent contraception preference were analysed.
MAIN RESULTS AND THE ROLE OF CHANCE
Retrospective analysis of serum β-hCG levels at admission indicated that 23.3% (158/678) of the women were pregnant. The success rate for pregnancy termination was 98.6% (136/138). Two women (1.5%, 2/138) had ongoing pregnancy that was subsequently terminated surgically. The overall bleeding induction rate within 7 days was 98.3% (639/650), with 100% (138/138) in pregnant participants and 97.9% (501/512) in non-pregnant participants. Most pregnant and non-pregnant participants experienced no significant menstrual disturbance during the treatment [96.3% (131/136) versus 97.6% (489/501)] or post-treatment [97.8% (133/136) versus 98.4% (493/501)] menstrual cycle. The general rate of satisfaction with the treatment was 96.7% (618/639). Generally, 36.0% (230/639) of participants preferred to use the regimen as a routine contraception method versus the 64.0% (409/639) who preferred to use it as a remedy for pregnancy prevention after unprotected sex (P < 0.001).
LIMITATIONS, REASONS FOR CAUTION
Study participants were recruited from a single region; further studies should include participants from multiple centres in different cities and nations. Given the uncertain efficacy of regimen reuse, the assessment of efficacy was based solely on the first treatment administration. Studies with larger samples and long-term follow-up may provide more data on whether repeated use of this regimen hampers its efficacy.
WIDER IMPLICATIONS OF THE FINDINGS
Menstrual regulation with low-dose mifepristone and misoprostol at expected menstruation can be efficacious and highly acceptable to maintain or restore non-pregnant status, which may have potential for routine contraception.
STUDY FUNDING/COMPETING INTEREST(S)
Support for this research was provided by the Start-Up Fund for Talents of the Third Affiliated Hospital of Guangzhou Medical University (2012), the Prevention and Control of Major Obstetric Disease major collaborative innovation project of the Educational Bureau of Guangzhou City (medical and health grant no. 13xt04, 2013), and the Collaborative Innovation Centre for Prevention and Control of Major Obstetric Disease collaborative innovation platform of the educational and financial departments of Guangdong Province (regional development grant, 2014). The authors declare no potential conflict of interest with respect to the research, authorship, and/or publication of this article.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>26405260</pmid><doi>10.1093/humrep/dev239</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-1161 |
| ispartof | Human reproduction (Oxford), 2015-12, Vol.30 (12), p.2794-2801 |
| issn | 0268-1161 1460-2350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1733192126 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Abortifacient Agents - administration & dosage Abortifacient Agents - therapeutic use Adolescent Adult Chorionic Gonadotropin - blood Contraceptive Agents - administration & dosage Contraceptive Agents - therapeutic use Drug Therapy, Combination Female Humans Menstrual Cycle - drug effects Menstruation - drug effects Middle Aged Mifepristone - administration & dosage Mifepristone - therapeutic use Misoprostol - administration & dosage Misoprostol - therapeutic use Pregnancy Treatment Outcome Young Adult |
| title | Feasibility and effectiveness of unintended pregnancy prevention with low-dose mifepristone combined with misoprostol before expected menstruation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A30%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20and%20effectiveness%20of%20unintended%20pregnancy%20prevention%20with%20low-dose%20mifepristone%20combined%20with%20misoprostol%20before%20expected%20menstruation&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=Li,%20Cui-Lan&rft.date=2015-12-01&rft.volume=30&rft.issue=12&rft.spage=2794&rft.epage=2801&rft.pages=2794-2801&rft.issn=0268-1161&rft.eissn=1460-2350&rft_id=info:doi/10.1093/humrep/dev239&rft_dat=%3Cproquest_cross%3E1733192126%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1733192126&rft_id=info:pmid/26405260&rft_oup_id=10.1093/humrep/dev239&rfr_iscdi=true |